Allogene Therapeutics, Inc.: shareholders and insiders

ALLONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.63

November 20, 2026Market cap $217M

What Ploutos Investor adds for Allogene Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 42% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.09 then, $0.63 on Nov 20, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Oct 23, 2026, from their own Form 4 filings.

10 Form 4s

Bought on the market

–

nobody

Sold on the market

$667.9K

6 people

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $667.9K by 6 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $667.9K by 6 people
  • Oct 21, 2026Geoffrey M. ParkerCHIEF FINANCIAL OFFICER
    Kind
  • Aug 21, 2026Earl Martin DouglasSVP, General Counsel
    Kind
  • Jun 18, 2026Joshua A KazamDirector
    Kind
  • Apr 21, 2026Annie YoshiyamaSVP, Finance
    Kind
  • Mar 31, 2026Benjamin Machinas BeneskiSVP, Chief Technical Officer
    Kind
  • Mar 16, 2026David D ChangPresident and CEO
    Kind
  • Mar 16, 2026Benjamin Machinas BeneskiSVP, Chief Technical Officer
    Kind
  • Mar 2, 2026Benjamin Machinas BeneskiSVP, Chief Technical Officer
    Kind
  • Feb 2, 2026Earl Martin DouglasSVP, General Counsel
    Kind
  • Feb 2, 2026Zachary RobertsEVP of R&D
    Kind
  • Feb 2, 2026Annie YoshiyamaSVP, Finance
    Kind
  • Feb 2, 2026Geoffrey M. ParkerCHIEF FINANCIAL OFFICER
    Kind
  • Feb 2, 2026David D ChangPresident and CEO
    Kind
  • Feb 2, 2026Benjamin Machinas BeneskiSVP, Chief Technical Officer
    Kind
  • Jan 21, 2026Zachary RobertsEVP of R&D
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 23, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ALLO's officers and directors from 2018 up to November 21, 2025, 8 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

3 Holders over 5%1 On a 13DNov 10, 2026 Latest filing
  • Pfizer Inc.
    Share of class9.00%
  • BlackRock, Inc.
    Share of class6.70%
  • Frazier Life Sciences Public Fund, L.P.with 9 more persons
    Share of class5.60%
Fell to 5% or less (8)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • State Street4.70%Nov 10, 202613G
  • TPG Gp A13D0.00%Sep 30, 202613D/A
  • Arie Belldegrun, M.D.3.90%Aug 7, 202613G/A
  • Lynx1 Capital Management LP0.00%May 15, 202613G/A
  • Citadel Advisors LLC2.80%May 15, 202613G/A
  • David D. Chang, M.D., Ph.D.4.90%May 13, 202613G/A
  • Capital World Investors0.00%Nov 13, 202513G/A
  • FMR4.90%Mar 7, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+143%
  • Millennium Mgmt (Englander)
    In the quarter+5.6%
  • Renaissance Technologies
    In the quarter+36%
  • Point72 (Cohen)
    In the quarter
  • D.E. Shaw
    In the quarter-9.5%
  • AQR Capital
    In the quarter-87%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 15.4% of its shares outstanding were held short, -4.0% since the report before.

Shares held short
53.41M
15.4%
Since the report before55.61M on Sep 30, 2026
-4.0%
9.3
5.78M
More days to cover thanof 4,578 US-listed companies with enough volume
89%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 34.03M
  • Nov 15, 2023: Shares held short 32.34M
  • Nov 30, 2023: Shares held short 31.86M
  • Dec 15, 2023: Shares held short 33.55M
  • Dec 29, 2023: Shares held short 31.32M
  • Jan 12, 2024: Shares held short 30.21M
  • Jan 31, 2024: Shares held short 23.09M
  • Feb 15, 2024: Shares held short 23.45M
  • Feb 29, 2024: Shares held short 25.01M
  • Mar 15, 2024: Shares held short 27.75M
  • Mar 28, 2024: Shares held short 30.62M
  • Apr 15, 2024: Shares held short 31.36M
  • Apr 30, 2024: Shares held short 33.87M
  • May 15, 2024: Shares held short 36.43M
  • May 31, 2024: Shares held short 40.57M
  • Jun 14, 2024: Shares held short 43.28M
  • Jun 28, 2024: Shares held short 41.38M
  • Jul 15, 2024: Shares held short 43.23M
  • Jul 31, 2024: Shares held short 37.75M
  • Aug 15, 2024: Shares held short 39.23M
  • Aug 30, 2024: Shares held short 38.94M
  • Sep 13, 2024: Shares held short 39.19M
  • Sep 30, 2024: Shares held short 38.51M
  • Oct 15, 2024: Shares held short 39.32M
  • Oct 31, 2024: Shares held short 37.04M
  • Nov 15, 2024: Shares held short 35.05M
  • Nov 29, 2024: Shares held short 31.17M
  • Dec 13, 2024: Shares held short 32.37M
  • Dec 31, 2024: Shares held short 30.91M
  • Jan 15, 2025: Shares held short 32.35M
  • Jan 31, 2025: Shares held short 32.05M
  • Feb 14, 2025: Shares held short 33.66M
  • Feb 28, 2025: Shares held short 39.10M
  • Mar 14, 2025: Shares held short 38.01M
  • Mar 31, 2025: Shares held short 34.76M
  • Apr 15, 2025: Shares held short 32.81M
  • Apr 30, 2025: Shares held short 30.13M
  • May 15, 2025: Shares held short 27.36M
  • May 30, 2025: Shares held short 24.57M
  • Jun 13, 2025: Shares held short 26.04M
  • Jun 30, 2025: Shares held short 26.57M
  • Jul 15, 2025: Shares held short 25.93M
  • Jul 31, 2025: Shares held short 24.45M
  • Aug 15, 2025: Shares held short 24.47M
  • Aug 29, 2025: Shares held short 19.94M
  • Sep 15, 2025: Shares held short 20.29M
  • Sep 30, 2025: Shares held short 19.20M
  • Oct 15, 2025: Shares held short 19.49M
  • Oct 31, 2025: Shares held short 19.09M
  • Nov 14, 2025: Shares held short 18.70M
  • Nov 28, 2025: Shares held short 18.66M
  • Dec 15, 2025: Shares held short 18.04M
  • Dec 31, 2025: Shares held short 18.08M
  • Jan 15, 2026: Shares held short 18.63M
  • Jan 30, 2026: Shares held short 18.82M
  • Feb 13, 2026: Shares held short 19.96M
  • Feb 27, 2026: Shares held short 23.93M
  • Mar 13, 2026: Shares held short 24.42M
  • Mar 31, 2026: Shares held short 32.06M
  • Apr 15, 2026: Shares held short 36.38M
  • Apr 30, 2026: Shares held short 36.86M
  • May 15, 2026: Shares held short 42.28M
  • May 29, 2026: Shares held short 44.48M
  • Jun 15, 2026: Shares held short 48.04M
  • Jun 30, 2026: Shares held short 63.39M
  • Jul 15, 2026: Shares held short 59.71M
  • Jul 31, 2026: Shares held short 60.75M
  • Aug 14, 2026: Shares held short 58.95M
  • Aug 31, 2026: Shares held short 59.11M
  • Sep 15, 2026: Shares held short 59.60M
  • Sep 30, 2026: Shares held short 55.61M
  • Oct 15, 2026: Shares held short 53.41M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading35.2% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 35.2% of the shares in the reported trades were short sales, against 30.5% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
35.2%
The 14 beforeOct 14, 2026 – Nov 2, 2026
30.5%
Change
+4.7 pts
Short sales a dayon average, of 8.51M shares
3.00M
More than atof 3,666 US-listed companies, same days
11%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 38.5%
  • Oct 15, 2026: Short sales 37.1%
  • Oct 16, 2026: Short sales 43.8%
  • Oct 19, 2026: Short sales 31.3%
  • Oct 20, 2026: Short sales 42.6%
  • Oct 21, 2026: Short sales 46.8%
  • Oct 22, 2026: Short sales 34.6%
  • Oct 23, 2026: Short sales 41.7%
  • Oct 26, 2026: Short sales 31.7%
  • Oct 27, 2026: Short sales 27.3%
  • Oct 28, 2026: Short sales 23.1%
  • Oct 29, 2026: Short sales 17.8%
  • Oct 30, 2026: Short sales 14.2%
  • Nov 2, 2026: Short sales 30.8%
  • Nov 3, 2026: Short sales 18.8%
  • Nov 4, 2026: Short sales 17.1%
  • Nov 5, 2026: Short sales 15.5%
  • Nov 6, 2026: Short sales 19.9%
  • Nov 9, 2026: Short sales 53.6%
  • Nov 10, 2026: Short sales 52.2%
  • Nov 11, 2026: Short sales 48.4%
  • Nov 12, 2026: Short sales 39.6%
  • Nov 13, 2026: Short sales 33%
  • Nov 16, 2026: Short sales 43%
  • Nov 17, 2026: Short sales 37.8%
  • Nov 18, 2026: Short sales 51.7%
  • Nov 19, 2026: Short sales 38.3%
  • Nov 20, 2026: Short sales 47.2%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

10.37M Insiders' shares4.26% Of the company
  • David D ChangPresident and CEO
    Directly5.15M
  • Arie BelldegrunDirector
    Directly–
  • Geoffrey M. ParkerCHIEF FINANCIAL OFFICER
    Directly1.05M
  • Zachary RobertsEVP of R&D
    Directly581.2K
  • Earl Martin DouglasSVP, General Counsel
    Directly488.3K
  • Joshua A KazamDirector
    Directly398.5K
  • Franz B HumerDirector
    Directly307.5K
  • Timothy L. MooreChief Technical Officer
    Directly250.7K
  • Benjamin Machinas BeneskiSVP, Chief Technical Officer
    Directly195.3K
  • Annie YoshiyamaSVP, Finance
    Directly124.5K
  • Deborah M. MessemerDirector
    Directly107.4K

A lower bound: it counts only the 11 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

17 ETFs holding it0.24% The largest weight (XBI)
  • XBIState Street(R) SPDR(R) S&P(R) Biotech ETF
    Weight in the fund0.24%
  • LABUDirexion Daily S&P Biotech Bull 3X Shares
    Weight in the fund0.16%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.05%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.04%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.04%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.02%
  • DFASDimensional U.S. Small Cap ETF
    Weight in the fund0.01%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.01%

17 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

209 Managers, Q2 2026$652M Value of their positions
  • Q3 2025: Managers 170
  • Q4 2025: Managers 172
  • Q1 2026: Managers 210
  • Q2 2026: Managers 209

Institutional investors by quarter

The fund managers holding ALLO, quarter by quarter, from Q1 2016 to Q2 2025, 28 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 209 managers held 313M shares, worth $652M. During the quarter 32 opened a position, 33 closed one, 96 added and 51 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+58%
  • Frazier Life Sciences Management
    In the quarter+491%
  • Pfizer
    In the quarter
  • State Street
    In the quarter+120%
  • TPG Gp A
    In the quarter
  • Sio Capital Management
    In the quarter
  • Primecap Management
    In the quarter+57%
  • Vanguard Capital Management
    In the quarter+76%
  • FMR
    In the quarter+655%
  • Citadel Advisors (Griffin)
    In the quarter+48%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Allogene Therapeutics's filings show?

Who buys and sells is one part of Allogene Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ALLO's shareholders

Didn't find what you were looking for?

Ask us
Have ALLO's insiders bought or sold?

From Jun 23, 2026 to Oct 23, 2026 Allogene Therapeutics's insiders bought 0 and sold $111.7K of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold ALLO?

6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $39M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.